# US 2008/0188817 A1 · Stable Liquid IL-1 Antagonist Formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188817 A1
- Document ID: US20080188817A1
- Status: Published application
- Kind: A1
- Application number: 12/048,717
- Filed: 2008-03-14
- Published: 2008-08-07
- Earliest claimed: 2004-08-17
- Assignees: Regeneron Pharmaceuticals, Inc.
- Inventors: Daniel Dix; Katherine Bowers; Chimanlall Goolcharran; Leu-Fen H. Lin
- Web page: https://patentgrep.com/patent/US20080188817A1

## CPC

- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 38/2006: {IL-1}
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion proteins having an amino acid sequence of SEQ ID NO: 10. Stable liquid formulations made with and without sodium chloride, and made with phosphate or histidine buffer, are provided.

## Claims

### Claim 1

A stable liquid formulation, comprising:
histidine at 40 mM, 3% PEG, 1% glycine, 50 mM arginine, 2% sucrose, and 10-100 mg/ml IL-1 trap that is a dimeric fusion protein comprising amino acid sequence SEQ ID NO:10, wherein the formulation has a pH of about 6.5.

### Claim 2 (depends on 1)

The stable liquid formulation of claim 1, wherein the PEG is PEG 3350.

### Claim 3 (depends on 1)

The stable liquid formulation of claim 1, wherein the IL-1 trap protein is present at about 80 mg/ml.

### Claim 4 (depends on 2)

A receptacle containing an amount of the stable liquid formulation of claim 2 extractable as a single dose.

### Claim 5 (depends on 4)

The receptacle of claim 4, wherein the single dose has a volume of about 1 ml to about 2 ml.

### Claim 6 (depends on 2)

A pre-filled syringe comprising a sterile preparation of a single dose of the stable liquid formulation of claim 2.

### Claim 7

A stable liquid formulation, comprising:
sodium phosphate at 40 mM, 3% PEG, 1% glycine, 50 mM arginine, 2% sucrose, and 10-100 mg/ml IL-1 trap that is a dimeric fusion protein comprising amino acid sequence SEQ ID NO:10, wherein the formulation has a pH of about 6.5.

### Claim 8 (depends on 7)

The stable liquid formulation of claim 7, wherein the PEG is PEG 3350.

### Claim 9 (depends on 7)

The stable liquid formulation of claim 7, wherein the IL-1 trap protein is present at about 80 mg/ml.

### Claim 10 (depends on 8)

A receptacle containing an amount of the stable liquid formulation of claim 8 extractable as a single dose.

### Claim 11 (depends on 8)

The receptacle of claim 8, wherein the single dose has a volume of about 1 ml to about 2 ml.

### Claim 12 (depends on 8)

A pre-filled syringe comprising a sterile preparation of a single dose of the stable liquid formulation of claim 8.

### Claim 13

A stable liquid formulation, comprising:
sodium phosphate at 10 mM, 50 mM NaCl, 3% PEG, 20% sucrose, and 10-100 mg/ml IL-1 trap that is a dimeric fusion protein comprising amino acid sequence SEQ ID NO:10, wherein the formulation has a pH of about 6.5.

### Claim 14 (depends on 13)

The stable liquid formulation of claim 13, wherein the PEG is PEG 3350.

### Claim 15 (depends on 13)

The stable liquid formulation of claim 13, wherein the IL-1 trap protein is present at about 50 mg/ml.

### Claim 16 (depends on 14)

A receptacle containing an amount of the stable liquid formulation of claim 14 extractable as a single dose.

### Claim 17 (depends on 16)

The receptacle of claim 16, wherein the single dose has a volume of about 1 ml to about 2 ml.

### Claim 18 (depends on 14)

A pre-filled syringe comprising a sterile preparation of a single dose of the stable liquid formulation of claim 14.
